1. Generics Bulletin
  2. >>Business

Hikma’s Olafsson Offers Latest On Advair And Vascepa Rivals

Among Four Key Aspects That Will Underpin US Generics Business In 2021

 
• By Dave Wallace

Four key “moving pieces,” including the next developments for rivals to Advair and Vascepa, will influence the success of Hikma’s US generics business, CEO Siggi Olafsson tells Generics Bulletin in the first part of an exclusive interview.

Four Cogs Hands Sunset
Four key “moving pieces” will influence the success of Hikma’s US generics business in 2021 • Source: Shutterstock

Four major “moving pieces” will influence the success of Hikma’s US generics business in 2021, CEO Siggi Olafsson has told Generics Bulletin in the first part of an exclusive interview.

These include the next steps for two of the company’s key products – in the form of its generic rivals to GlaxoSmithKline’s Advair (fluticasone/salmeterol) and Amarin’s Vascepa (icosapent ethyl) – as well

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

More from Business

Pfizer Discusses Tariffs Amid International Slump For Oncology Biosimilars Revenue

 
• By Adam Zamecnik

Reflecting conversations across the wider pharmaceutical industry, Pfizer’s earnings call for the first quarter of 2025 focused on the sector’s response to the potential imposition of tariffs by the Trump administration.

Amneal Proud To Be ‘Made In America’ And Ready To Scale Up Its US Manufacturing

 
• By Urtė Fultinavičiūtė

Amneal has set itself apart from competitors who are scrambling to find alternatives if proposed US pharmaceutical tariffs come into place. For the New Jersey-based firm, this is an opportunity to embrace its American identity and open a new chapter of growth.

‘I’ll Be Happy When We Have 40-Plus Assets’ – Sandoz Builds Up Biosimilars

 
• By Dave Wallace

With biosimilars playing an increasingly important role in Sandoz’s business, the firm’s first-quarter results call saw management lay out the latest key developments. Meanwhile, the company also addressed the issue of US tariffs, voicing optimism over both future developments as well as its ability to weather current measures.